treatment of egg allergy. The company also announced an exclusive supply agreement for egg protein with Michael Foods, Inc.
Aimmune expects to initiate a Phase 2 clinical trial of AR201 for the treatment of egg allergy in 2019.
The agreement with Michael Foods includes all of the company’s egg products, worldwide, and gives Aimmune exclusive access to the clinical and commercial use of Michael Foods egg products for any egg allergy treatment, prevention or cure for a period of up to 15 years beyond the potential approval of AR201.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.